Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BRII-196 and BRII-198 in COVID-19
NCT04787211Phase 2Completed
- Sponsor
- Brii Biosciences
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of amubarvimab and romlusevimab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Brii Biosciences. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 7 more. Started Jun 2021; status: completed.
02
Drugs
amubarvimabromlusevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04787211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787211.